New Diagnostics Working Group

Annual Meeting 2013
Paris, 31 October 2013

Daniela Cirillo (San Raffaele Scientific Institute)
Co-Chair, NDWG
New Diagnostics Working Group

Fostering development of new diagnostic tools for TB

Vision
High quality diagnosis of tuberculosis and drug resistance is available for all people in all settings.

Mission
Foster development and evaluation of new diagnostics for tuberculosis by providing strategic direction and serving as a coordination, communication and advocacy platform for all stakeholders in TB diagnostic research and development.
Connecting partners

The NDWG serves as a forum for stakeholders, provides a coordination and communication platform for effective collaboration and develops technical resources towards delivery of new TB diagnostics, by

1. Setting strategic direction and providing guidance
2. Assuring coordination between partners
3. Establishing mechanisms for strategic information and knowledge sharing
4. Identifying and promoting promising innovation
5. Advocating for new TB diagnostics, for increased funding for TB diagnostic R&D and for evidence-based decision making to drive WHO policy
Strategic projects

• Develop an overarching research strategy to coordinate different players in TB diagnostic R&D:
  – To identify mechanisms to improve information and data sharing among researchers
  – Convene Stakeholder Forums as part of the process

• Monitor progress in TB diagnostic development and issue global TB diagnostic pipeline
Ongoing activities

- Collaborate with other Stop TB Partnership Working Groups and other initiatives, such as the GLI and the CPTR
- Organize NDWG Annual Meeting in conjunction with Union Conference and participate in scientific meetings
- Ensure dissemination to membership and partners of regular updates and news, as well as NDWG-developed resources and outcomes of projects
- Provide advocacy and disseminate materials at relevant meetings and events
- Use resources made available by the Stop TB Partnership to leverage funds from other donors in order to finance major initiatives.
Stakeholder Forum

Rapid resistance testing for TB drugs: identifying the priority medical needs

On 17-18 March 2014 in Geneva, Switzerland jointly organized with GLI/WHO and FIND

Objectives

• Address the needs related to rapid drug resistance assays to be performed at peripheral level to inform individual treatment decisions

• Address key questions faced by test developers and identify the best compromise between current medical needs and needs generated by the roll-out of new regimens.
Stakeholder Forum

*Rapid resistance testing for TB drugs: identifying the priority medical needs*

Program outline

- Review the current medical needs for rapid DST
- Provide potential scenarios of future MDR-TB regimens
- Update on the current knowledge regarding the characterization of mutations that confer resistance to TB drugs and correlation between phenotypic and genotypic resistance
- Present completed and ongoing modeling studies looking at impact for TB testing and review key outcomes
- Provide an update on the technological advances and methodologies to detect mutations that confer drug resistance;
- Identify the priority drugs that should be targeted by rapid assays for drug resistance detection.
NDWG Core Group

Co-Chairs
Dr. Mark Perkins, FIND
Dr. Daniela Cirillo, San Raffaele Research Institute

Core Group Members (and constituency)
• Dr. Martina Casenghi, MSF (NGOs)
• Dr. Anne Detjen, IUATLD/TB TREAT, USA (IUATLD)
• Dr. Christopher Gilpin, WHO Stop TB Department (WHO)
• Dr. Rumina Hasan, Aga Kahn University, (GLI)
• Philippe Jacon, Cepheid (Industry)
• Mayowa Joel, Communication for Development Centre, Nigeria (Patient Community)
• Dr. Arend Kolk, University of Amsterdam (Academia)
• Dr. John Ridderhof, CDC Atlanta, (CDC)
• Dr. Charles Sandy, National TB Program, Zimbabwe (NTP)

Subgroups and Coordinators
Drug Susceptibility Testing
Point-of-Care Diagnostics Dr. Ruth McNerney (LSHTM)
Diagnosis of Latent TB Infection Dr. Keertan Dheda (University of Cape Town) and Dr. Philip Hill (University of Otago) (jointly)
Evidence Synthesis and Policy Dr. Karen Steingart (University of Washington)
Childhood TB and Diagnostics Dr. Anneke Hesseling (Stellenbosch University)
Community, Poverty and Advocacy Mayowa Joel (Communication for Development)

Secretariat Alessandra Varga, FIND
New Diagnostics Working Group

NDWG@finddiagnostics.org

http://www.stoptb.org/wg/new_diagnostics/